Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04247620
Other study ID # H-45360
Secondary ID 1R01DK119246
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 15, 2020
Est. completion date June 30, 2024

Study information

Verified date July 2023
Source Baylor College of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

DiaBetter Together is a strengths-based peer support intervention delivered to young adults (age 17-25) by trained Peer Mentors (age 20-35) during the transition between pediatric and adult diabetes care. The aims of this proposed randomized controlled trial are to evaluate the impact of the intervention on glycemic control (primary), time to first adult care visit, adherence, and psychosocial outcomes (secondary) in young adults with T1D after 12 months.


Description:

DiaBetter Together is a strengths based peer support intervention delivered to young adults (age 17-25) by trained Peer Mentors (age 20-35) during the transition between pediatric and adult diabetes care. The study aims to optimize transition in T1D by leveraging and building on young adults' diabetes strengths, self-management skills, and social supports. This intervention will maximize protective processes that can facilitate optimal transition by training Peer Mentors (experienced young adults with T1D who have successfully established care in an adult setting) to provide relevant information about successful transition, teach strengths-based skills for managing transition-related challenges, share personal transition-related experiences, encourage young adults to access their social support network, and serve as a positive role model. Delivery of these strengths-based intervention components through a Peer Mentor has potential to reduce isolation, increase access to relevant information, and facilitate engagement with self-management and T1D care. This intervention is a complement to existing systems of care for young adults with T1D for 12 months as they leave the pediatric setting.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 144
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 17 Years to 35 Years
Eligibility Young Adult Inclusion/Exclusion Criteria Inclusion Criteria: - has a diagnosis of type 1 diabetes of at least 1 year - currently receiving care at a Texas Children's Hospital Diabetes Care Center location - is between the ages of 17-25 years at enrollment - exhibits fluency in reading/speaking English - their endocrine provider confirmed plans to transfer to adult provider in the next 6 months Exclusion Criteria: - serious medical, cognitive, or mental health comorbidity that would preclude ability to provide informed consent or participate in data collection or intervention Peer Mentor Inclusion/Exclusion Criteria Inclusion Criteria: - was diagnosed with type 1 diabetes before age 18 - has a diagnosis of type 1 diabetes of at least 1 years - is between the ages of 20-35 at enrollment - has been previously treated in pediatric care and is currently treated in adult care - demonstrated interest and ability to effectively deliver the peer intervention & - exhibits fluency in reading/speaking English Exclusion Criteria: - serious medical, cognitive, or mental health comorbidity that would preclude ability to fulfill role or complete questionnaires.

Study Design


Intervention

Behavioral:
DiaBetter Together
Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).
Peer Mentor Delivery
Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.

Locations

Country Name City State
United States Baylor College of Medicine Houston Texas

Sponsors (3)

Lead Sponsor Collaborator
Baylor College of Medicine Children's National Research Institute, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glycemic Control (HbA1c) HbA1c is the average blood glucose over 3-4 months. The American Diabetes Association recommends an HbA1c target of <7.0%. HbA1c is collected via fingerstick/blood assay at routine diabetes visits and will be extracted from the medical record at each clinic visit during the study period.
At Baseline and 12 months, HbA1c will be collected using the following methods:
Collection of most recent HbA1c from review of electronic medical chart (Texas Children's or Baylor College of Medicine) or medical records from outside provider (obtained with written permission from participant).
A dried blood spot at-home Hemoglobin A1c kit (Whatman 903 card, BD Microtainer HI-Flow Contact-Activated Lancet) will be mailed to the participant to complete and return to the study team for analysis on the Vitros 4600 HbA1c assay (correlated with the DCA 2000).
Collected for young adult participants in both arms, not Peer Mentors.
Baseline through 12-Month Post-Randomization
Secondary Time to First Adult Care Visit Time will start on the date of the last pediatric care visit (may differ from date of enrollment in study). The event of interest is the date of the first adult care visit. Participants who do not follow-up with an adult care provider within 12 months of the last pediatric visit will be censored for the event at the 12-month time point.
Collected for young adult participants in both arms, not Peer Mentors.
12-Month Post-Randomization
Secondary Diabetes Self-Management/Adherence (Self-Care Inventory-Revised, Short Form) The Self-Care Inventory-Revised, Short Form (SCI-RSF) is a 9-item measure that asks respondents the frequency with which they completed diabetes self-management tasks in the past 1-2 months. Item responses range from (1) Never to (5) Always, higher scores = higher adherence.
Collected for young adult participants in both arms (baseline, 6 mo, 12 mo) and Peer Mentors (pre- and post-involvement in study).
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary Health-Related Quality of Life (Type 1 Diabetes and Life) The Type 1 Diabetes and Life (T1DAL) measure assesses diabetes-specific health-related quality of life. Participants will complete the T1DAL version for their age (Adolescent: 12-17, 23 items; Young Adult: 18-25, 27 items; Adult-1: 26-45, 27 items), which asks respondents to rate the degree to which each item is true about their everyday quality of life with diabetes. Items responses range from 1 (not at all true) to 5 (very true) and total and sub-scales scores are calculated from 1-100 (higher = better quality of life).
Collected for young adult participants in both arms (baseline and 12 mo) and Peer Mentors (pre- and post-involvement in study).
Baseline and 12-Month Post-Randomization
Secondary Diabetes Strengths (Diabetes Strengths and Resilience measure) The Diabetes Strengths and Resilience (DSTAR) measure assesses participants' self-perceptions about what they do well with diabetes (known as diabetes strengths). Participants will complete the Young Adult version of the DSTAR, which asks respondents to rate how often the items represent their experiences/perspectives about their diabetes strengths. Items responses range from 0 (never) to 4 (almost always) and are calculated for total and subscale scores (higher = more strengths).
Collected for young adult participants in both arms, not Peer Mentors.
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary Social Support (Brief 2-Way Social Support Scale) The Brief 2-Way Social Support Scale (Brief-2SSS) is a 12-item measure that assesses participants' experiences of giving and receiving social support. There are four scales: giving emotional support, giving instrumental support, receiving emotional support, and receiving instrumental support. Items responses range from 0 (not at all) to 5 (always) and are calculated for total and subscale scores (higher = more perceived support).
Collected for young adult participants in both arms (baseline, 6, & 12 mos) and Peer Mentors (pre- and post-involvement in study).
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary Diabetes Distress (Diabetes Distress Scale for Adults with T1D) The Diabetes Distress Scale for Adults with T1D (DDS-T1D) is a 28-item self-report scale that measures participants' experiences with distress related to living with diabetes. It assesses seven dimensions of distress: powerlessness, management distress, hypoglycemia distress, negative social perceptions, eating distress, physician distress, and friends/family distress. Items responses range from 1 (not a problem) to 6 (a very serious problem) and are calculated for total and subscale scores (higher = more distress).
Collected for young adult participants in both arms (baseline, 6 mo, 12 mo) and Peer Mentors (pre- and post-involvement in study).
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary Depressive Symptoms (PROMIS Short Form Depression 4a) The PROMIS Short Form Depression 4a consists of 4 items that are pulled from the PROMIS Depression Item Bank v1.0. These items assess how often the individual has been bothered by depression-related symptoms, including negative mood (sadness, guilt), views of self (self-criticism, worthlessness), and social cognition (loneliness, interpersonal alienation), and decreased positive affect and engagement (loss of interest, meaning, and purpose), over the last 7 days. Items responses range from 1 (never) to 6 (always) and are calculated into a total score (higher = more depressive symptoms).
Collected for young adult participants in both arms, not Peer Mentors.
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary Emotional Support (PROMIS Short Form Emotional Support 4a) The PROMIS Short Form Emotional Support 4a assesses perceived feelings of being cared for and valued as a person and having supportive relationships. Participants respond to 4 items on a scale from 1(Never) to 5 (Always) and are calculated into a total score (higher = more perceived support).
Collected for young adult participants in both arms, not Peer Mentors.
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary Informational Support (PROMIS Short Form Informational Support 4a) The PROMIS Short Form Informational Support 4a assesses perceptions about the information or resources others provide to them (adequacy, availability, helpfulness). Participants respond to 4 items on a scale from 1(Never) to 5 (Always) and are calculated into a total score (higher = more perceived support).
Collected for young adult participants in both arms, not Peer Mentors.
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary Social Isolation (PROMIS Short Form Social Isolation item) The PROMIS Short Form Social Isolation item is a single-item measure from the PROMIS item bank that assesses participants' feelings of being isolated from other people. There is no time frame for responding to this measure. Participants respond to 1 item on a scale from 1 (Never) to 5 (Always), which is calculated into a total score (higher = more perceived isolation).
Collected for young adult participants in both arms (baseline, 6, & 12 mos), not Peer Mentors.
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary Transition Readiness (Readiness Assessment of Emerging Adults With Type 1 Diabetes Diagnosed in Youth) The Readiness Assessment of Emerging Adults With Type 1 Diabetes Diagnosed in Youth (READDY) is a 46-item self-report scale that measures participants' preparation for the transition to adult diabetes care, including: knowledge of diabetes, navigation of diabetes care, management skills and behaviors, and insulin pump skills if applicable. Only 18 items from the 3 subscales [Knowledge (4 items - baseline and 12 mos only), Navigation (13 items, baseline, 6 and 12 mos), Health Behaviors (1 item, baseline and 12 mo only)] will be administered for this study. Items responses range from 0 (haven't thought about it) to 5 (yes, I can do this) and are calculated for a total score (higher = more ready).
Collected for young adult participants in both arms (baseline, 6, & 12 mos), not Peer Mentors.
Baseline, 6-Month Post-Randomization, & 12-Month Post-Randomization
Secondary General Quality of Life (Satisfaction with Life Scale) The Satisfaction with Life Scale (SWLS) is a 5-item self-report scale that measures participants' perceptions about their life overall. Items responses range from 1 (strongly disagree) to 7 (strongly agree) and are calculated for a total score (higher = better quality of life).
Collected for young adult participants in both arms (baseline and 12 mo), not Peer Mentors.
Baseline and 12-Month Post-Randomization
Secondary Subjective Sleep Experiences (Pittsburgh Sleep Quality Index - Revised) The Pittsburgh Sleep Quality Index (PSQI) - Revised is a 9-item, self-report scale that measures several aspects of participants' sleep, including subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, and diabetes-related sleep disturbance (new items - not in original measure). This revised version excludes the following components from the original measure: daytime dysfunction and use of sleep-promoting medication. Participants complete 4 open-ended items on sleep latency, efficiency, and duration, 4 scaled-response items on sleep disturbance and diabetes-related sleep disturbance ranging from 0 (Not during past month) to 3 (Three or more times a week), and 1 scaled-response item on subjective sleep quality ranging from 0 (Very good) to 3 (Very bad). A global score is not calculated; subscales are calculated independently (higher = worse sleep quality).
Collected for young adult participants in both arms (baseline and 12 mo), not Peer Mentors.
Baseline and 12-Month Post-Randomization
Secondary COVID-19 Protective Behaviors (Oelsner MESA COVID-19 - Revised) The Oelsner MESA COVID-19 - Revised is a 10-item self-report scale that measures participants' social distancing and hygiene behaviors during the COVID-19 pandemic. Participants rate how often they engaged in specific precautionary behaviors at the peak of the pandemic (Spring/Summer 2020) and over the past month. Item responses range from 0 (Never) to 4 (Always) and are calculated for a total score (higher = engaged in precautionary behaviors more frequently).
Collected for young adult participants in both arms (baseline and 12 mo) and Peer Mentors (pre-involvement in study).
Baseline and 12-Month Post-Randomization
Secondary COVID-19 Experiences (COVID-19 Experiences Questionnaire for Young Adults with T1D) The COVID-19 Experiences Questionnaire for Young Adults with T1D (CEQ-YAD) is a 37-item, self-report questionnaire assessing how the COVID-19 pandemic impacted young adults with type 1 diabetes, including items about: (1) overall impact of the COVID-19 pandemic, (2) changes in life circumstances due to the pandemic, (3) self and family exposure to COVID-19, (4) changes in diabetes management due to the pandemic, (5) changes in everyday activities and mood due to the pandemic, and (6) COVID-19 vaccine uptake (number, dates, and manufacturers of vaccines and boosters received; open-text about reasons for not being vaccinated). It uses mixed-methods, including scaled, Yes/No, and open-ended items asking about participants' experiences during the peak of the pandemic (Spring/Summer 2020) and over the past 12 months. A total score is calculated by summing response values from scaled and Yes/No items (higher = most negative/worst impact from COVID-19 pandemic). Baseline and 12-Month Post-Randomization
Secondary Stressful Events (Stressful Event Questionnaire) The Stressful Event Questionnaire assess the number and types of stressful life events experienced during the past year. Participants are asked to select any stressful life events from a list (for example: financial stressors, legal troubles, change in employment, etc.) and to include any stressful events experienced that are not already listed. A total score is calculated by summing the number of events selected or included by the participant (higher = more stressful live events experienced).
Collected for young adult participants in both arms (baseline and 12 mo), not Peer Mentors.
Baseline and 12-Month Post-Randomization
Secondary Social Vulnerability (CDC/ATSDR Social Vulnerability Index) The CDC/ATSDR Social Vulnerability Index (SVI) uses 15 US census-tract level social variables grouped into four related themes, including (1) socioeconomic status (below poverty, unemployed, income, no high school diploma), (2) household composition & disability (aged 65 or older, aged 17 or younger, older than age 5 with a disability, single-parent households), and minority status & language (minority, speak English "less than well"), housing type & transportation (multi-unit structures, mobile homes, crowding, no vehicle, group quarters). Participants' address-level data collected at baseline are batch geocoded, transforming addresses into geographical coordinates using ArcGIS Pro Desktop software and the Street Map Premium package. Coordinates are intersected with census tract polygons, which can be linked to extant data tables, including variables in the SVI. A tract-level score for each of the four themes and an overall score measuring social vulnerability are obtained. Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4